Bicycle Therapeutics Limited

General Information


We are a clinical-stage biopharmaceutical company developing a novel class of medicines, which we refer to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained to form two loops which stabilize their structural geometry. This constraint is designed to confer high affinity and selectivity and the relatively large surface area presented by the molecule allows targets to be drugged that have historically been intractable to non-biological approaches. Bicycles are a unique therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic, or PK, properties of a small molecule. Bicycles are excreted by the kidney rather than the liver and have shown no signs of immunogenicity to date, which we believe together support a favorable toxicological profile.

Employees: 61
Founded: 2009
Contact Information
Address B900, Babraham Research Campus, Cambridge, CB22 3AT, United Kingdom
Phone Number +44 1223 261503.
Web Address
View Prospectus: Bicycle Therapeutics Limited
Financial Information
Market Cap $247.7mil
Revenues $7.1 mil (last 12 months)
Net Income $-21.8 mil (last 12 months)
IPO Profile
Symbol BCYC
Exchange NASDAQ
Shares (millions): 4.3
Price range $14.00 - $14.00
Est. $ Volume $60.7 mil
Manager / Joint Managers Goldman Sachs/ Jefferies/ Piper Jaffray
CO-Managers Canaccord Genuity
Expected To Trade: 5/23/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change